Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US

References

• Prichard M, Harris T, Williams M, et al. Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma. Expert Opin Pharmacother. 2009;10(6):983–995.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Int Agency Res cancer. 2008;2:5019.
   Google Scholar
• National Cancer Institute. Surveillance, epidemiology, and end results program. Cancer stat facts: non-Hodgkin lymphoma; 2021 [cited 2021 Sep 20]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html.
   Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2016, National Cancer Institute. Bethesda, MD, based on November 2018 SEER data submission, posted to the SEER web site; April 2019 [cited 2019 July 17]. Available from: https://seer.cancer.gov/csr/1975_2016/.
   Google Scholar
• Ernst M, Oeser A, Besiroglu B, Cochrane Haematology Group, et al. Chimeric antigen receptor (CAR) T‐cell therapy for people with relapsed or refractory diffuse large B‐cell lymphoma. Cochrane Database Syst Rev. 2021;9(9):CD013365.
   PubMedGoogle Scholar
• Chaganti S, Illidge T, Barrington S, British Committee for Standards in Haematology, et al. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016;174(1):43–56.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Ghielmini M, Rule S, ESMO Guidelines Committee, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines For diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v83–v90.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Seymour J, Martelli M, ESMO Guidelines Committee, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v91–v102.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490–3496.
   PubMed Web of Science ®Google Scholar
• Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017;179(1):50–60.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
   PubMed Web of Science ®Google Scholar
• Lin JK, Muffly LS, Spinner MA, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. J Clin Oncol. 2019;37(24):2105–2119.
   PubMed Web of Science ®Google Scholar
• Roth JA, Sullivan SD, Lin VW, et al. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States. J Med Econ. 2018;21(12):1238–1245.
   PubMed Web of Science ®Google Scholar
• Tice JA, Walsh JME, Otuonye I, et al. Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value evidence report. Boston, MA: Institute for Clinical and Economic Review; 2018.
   Google Scholar
• Whittington MD, McQueen RB, Ollendorf DA, et al. Long-term survival and cost-effectiveness associated with axicabtagene ciloleucel vs chemotherapy for treatment of B-Cell lymphoma. JAMA Netw Open. 2019;2(2):e190035.
   PubMed Web of Science ®Google Scholar
• Liu R, Oluwole OO, Diakite I, et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J Med Econ. 2021;24(1):458–468.
   PubMed Web of Science ®Google Scholar
• Oluwole OO, Chen JM, Chan K, et al. Matching-adjusted indirect comparison (MAIC) of axicabtagene ciloleucel (Axi-Cel) and lisocabtagene maraleucel (Liso-Cel) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more prior lines of therapy. Presented at: 9th annual meeting of the Society of Hematologic Oncology (SOHO 2021); Sept 8–11; virtual. Abstract ABCL-289. 2021.
   Google Scholar
• National Institute for Health and Care Excellence. Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies. Technology appraisal guidance [TA559]; 2019 [Published 2019 Jan23]. Available from: https://www.nice.org.uk/guidance/ta559.
   Google Scholar
• Centers for Medicare & Medicaid Services. Physician fee schedule [Internet]; 2019 [cited 2019 May 3]. Available from https://www.cms.gov/apps/physician-fee-schedule/search/search-criteria.aspx.
   Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. 2020;396(10254):839–852.
   PubMed Web of Science ®Google Scholar
• IBM Micromedex. RED BOOK Online; 2019 [cited 2019 December 3]. Available from: http://micromedex.com.
   Google Scholar
• Bachier CR, Palomba ML, Abramson JS, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) in three ongoing clinical studies in relapsed/refractory (r/r) B cell non-Hodgkin lymphoma (NHL), including second-line transplant ineligible patients: Transcend NHL 001, Outreach, and PILOT. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Bureau of Labor Statistics. Consumer price index. Medical care component; 2020a [cited 2020 February 21]. Available from: https://data.bls.gov/timeseries/CUUR0000SAM?output_view=data.
   Google Scholar
• Gershengorn HB, Garland A, Gong MN. Patterns of daily costs differ for medical and surgical intensive care unit patients. Annals ATS. 2015;12(12):1831–1836.
   Google Scholar
• Bureau of Labor Statistics. Consumer price index. Medical care component; 2021 [cited 2021 August 11]. Available from: https://data.bls.gov/timeseries/CUUR0000SAM?output_view=data.
   Google Scholar
• Agency for Healthcare Research and Quality. Healthcare cost and utilization project (HCUP); 2016 [cited 2020 January 6]. Available from: https://hcupnet.ahrq.gov.
   Google Scholar
• Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10(7):366–374.
   PubMed Web of Science ®Google Scholar
• Huntington S, Keshishian A, McGuire M, et al. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leuk Lymphoma. 2018;59(12):2880–2887.
   PubMed Web of Science ®Google Scholar
• Kutikova L, Bowman L, Chang S, et al. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leuk Lymph. 2006;47(8):1535–1544.
   PubMed Web of Science ®Google Scholar
• Lin V, Jiang Y, Chuang L, et al. Health utilities for patients with relapsed or refractory large B-cell lymphoma: ad hoc analysis from an axicabtagene ciloleucel safety management study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation, Lisbon, Portugal, 2018.
   Google Scholar
• Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymphoma. 2018;59(7):1700–1709.
   PubMed Web of Science ®Google Scholar
• Abramson JS, Siddiqi T, Garcia J, et al. Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial. Blood Adv. 2021;5(6):1695–1705.
   PubMed Web of Science ®Google Scholar
• Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol. 2015;33(13):1467–1474.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER’s reference case for economic evaluations: principles and rationale. Boston, MA: Institute for Clinical and Economic Review; 2020.
   Google Scholar
• Bansal A, Sullivan SD, Lin VW, et al. Estimating long-term survival for patients with relapsed or refractory large B-Cell lymphoma treated with chimeric antigen receptor therapy: a comparison of standard and mixture cure models. Med Decis Making. 2019;39(3):294–298.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades A, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12(1):9.
   PubMed Web of Science ®Google Scholar
• Huet S, Kaddour A. Maximum likelihood estimation in survival analysis with grouped data on censored individuals and continuous data on failures. J Royal Statist Soc. 1994;43(2):325–333.
   Google Scholar
• Centers for Disease Control and Prevention. National vital statistics system. Mortality: life tables US 2015; 2019. Available from: https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/NVSR/67_07/Table02.xlsx(males) https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/NVSR/67_07/Table03.xlsx(females).
   Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: OUP; 2006.
   Google Scholar
• Büyükkaramikli NC, Rutten-van Mölken MP, Severens JL, et al. TECH-VER: a verification checklist to reduce errors in models and improve their credibility. Pharmacoeconomics. 2019;37(11):1391–1408.
   PubMed Web of Science ®Google Scholar
• Parker C, Liu FF, Deger K, et al. Cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Presented at: 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; Dec 11, Atlanta, Georgia or virtual. Abstract 3003; 2021.
   Google Scholar
• Neelapu SS, Rossi JM, Jacobson CA, et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. Washington, DC: American Society of Hematology; 2019.
   Google Scholar
• Oluwole OO, Jansen JP, Lin VW, et al. Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020;26(9):1581–1588.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Kuruvilla J, Liu FF, et al. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma. J Hematol Oncol. 2021;14(1):1–17.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Kuruvilla J, Fox CP, et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Blood. 2020;136(Supplement 1):18–19.
   Google Scholar
• Schuster SJ, Zhang J, Yang H, et al. Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison. Leuk Lymphoma. 2022;63(4):845–854.
   PubMed Web of Science ®Google Scholar
• Seyedin R, Snider JT, Rajagopalan K, et al. Chimeric antigen receptor T-cell therapy treatment patterns: a retrospective cohort analysis of relapsed or refractory diffuse large B-Cell Lymphoma Patients In The US. Presented at: 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; Dec 11, Atlanta, Georgia or virtual. Abstract 1424; 2021.
   Google Scholar
• Oluwole OO, Jansen JP, Lin VW, et al. Response to letter to editor regarding "comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma. Biol Blood Marrow Transplant. 2020;26(12):e335–e336.
   PubMed Web of Science ®Google Scholar
• Westin JR, Kersten MJ, Salles G, et al. Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: observations from the JULIET, ZUMA‐1, and TRANSCEND trials. Am J Hematol. 2021;96(10):1295–1312.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Powers A, Jun MP, et al. Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma. Blood Adv. 2021;5(8):2245–2255.
   PubMed Web of Science ®Google Scholar